Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial
about
sameAs
Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reportsPrevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirinThe effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosaPrimary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national surveyReview article: gastrointestinal bleeding with low-dose aspirin - what's the risk?Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategiesPrimer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risksThe impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitorSurface phospholipids in gastric injury and protection when a selective cyclooxygenase-2 inhibitor (Coxib) is used in combination with aspirinGastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defenceSystematic review with meta-analysis: the gastrointestinal benefits of COX-2 selective inhibitors with concomitant use of low-dose aspirin.Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillanceNMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor.Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insightsPrevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON)Risk management of risk management: Combining proton pump inhibitors with low-dose aspirinProblem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs.Emerging roles for cyclooxygenase-2 in gastrointestinal mucosal defense.Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs.Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice?Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study.Myths and facts in the use of anti-inflammatory drugs.Peptic ulcer disease risk in chronic kidney disease: ten-year incidence, ulcer location, and ulcerogenic effect of medications.NSAID gastropathy and enteropathy: distinct pathogenesis likely necessitates distinct prevention strategiesPrevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors.Pharmacokinetic and clinical evaluation of esomeprazole and ASA for the prevention of gastroduodenal ulcers in cardiovascular patients.Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy.Optimizing the use of aspirin for cardiovascular prevention.Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?Polypharmacy of osteoarthritis: the perfect intestinal storm.Recent Advances in NSAIDs-Induced Enteropathy Therapeutics: New Options, New Challenges.Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective.Drug-disease interactions: narrative review of aspirin in gastric ulcer.Nonsteroidal Anti-Inflammatory Drug-Induced Gastroduodenal Bleeding: Risk Factors and Prevention Strategies.Histamine-2 Receptor Antagonist Cannot Prevent Recurrent Peptic Ulcers in Patients With Atherosclerotic Diseases Who Receive Platelet ADP Receptor Antagonist Monotherapy: A Randomized-Controlled, Double-Blind, and Double-Dummy Trial.Evidence-based clinical practice guidelines for peptic ulcer disease 2015.Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole.Advent of novel phosphatidylcholine-associated nonsteroidal anti-inflammatory drugs with improved gastrointestinal safety.New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment.Novel selective inhibitors of hydroxyxanthone derivatives for human cyclooxygenase-2.
P2860
Q24816687-3F0E4685-4002-440B-806E-D1170795F352Q28192701-4CE1DB55-EF1B-4CF3-AEF0-627E85843172Q28194351-B41C0F3E-BA59-47B7-BEB6-FF1B745DAB84Q28195079-5DD66F38-82D6-4CBF-B198-6EFA6F6FBCFBQ28200403-FC2AE384-61E4-4C20-901E-3DED2545024AQ28200569-9BC53835-76CA-4B34-8ED3-8337EE7231CEQ28200571-21944FD1-C630-4CD9-A299-19C77D78ACE6Q28217400-7E22B7F2-D353-4AB0-97FD-9AF96F7E1F31Q28219464-781BD723-E800-4E48-BDE0-B019F8E8C95FQ28482202-79AF8D62-71A1-4EFD-8D28-1001AA0E0ECCQ30248439-38890D09-07F1-470A-8556-6D1D9F66DE59Q33516504-22725B0D-4C49-4C6B-A722-C4CFD1372327Q34464035-EA8EE160-3A2C-4C5A-B071-1E7E23F23055Q34663572-8A25657E-F4F2-4AD8-9BD8-814051AC3ED4Q34935769-8064CF20-452F-49F1-8836-E0DD94904B8EQ35026472-BA38A1A3-C4B9-468F-975A-0C79C32A3019Q35636594-3133901E-9793-4992-AD11-694F68D9B6D2Q36075305-FDD86777-B477-4B4F-9E08-8BED4A2DCD5AQ36570803-A1D57E86-EC3B-4038-A242-D843309B8159Q36942298-C9C83CAC-9BE7-44BB-BECA-11E922D59298Q37327687-F6477855-05AD-4F8A-BEA9-45825EAB1518Q37476911-0F6FA90F-E918-41D9-8349-06C339C37A73Q37549220-DF8BAF4F-E6FC-410C-82DC-183E62C027E4Q37882741-F88E92D0-96B5-4538-90C6-4A1AE33F4F79Q37893966-9FD9D196-5E36-4857-9516-3FF829D9583CQ38030989-1F118A16-22A8-4E91-99E7-4683E0CC2E16Q38097424-DB241A9A-A8B6-4B92-9967-1149AB22E7BCQ38107179-6D51725F-6CED-41E5-92D0-835CE6C4F90EQ38114868-306DE3CF-4269-488D-899A-699CA440DC32Q38124006-B6992814-8913-4D3B-AECB-5AABCE2C010AQ38155495-7D89ACB2-D9D8-424B-A41F-C9E3EFF64E05Q38321114-D051C379-2339-4BEA-808E-05A5FE67B021Q38870495-7934D53B-F64F-49A0-BF2A-C73A651BC2D5Q38974392-2AC9C21D-8466-4F04-928D-B6B014BB16E5Q40422122-22BB2D53-528E-436C-9688-B07D09B83457Q40790399-D77ECFEE-580E-40F6-B4C3-C2FD3E19AF67Q43235331-0E99F408-936B-45BF-A13C-E5548B9AE412Q43247710-66CD8FB7-DA7F-4105-8012-366BABB3ECABQ45019665-7EA66A87-CA80-410A-9973-3712C11AEDD0Q46887247-70B03EFC-7424-4C3E-98B0-DDB95255D928
P2860
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial
description
2004 nî lūn-bûn
@nan
2004 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Ulcer formation with low-dose ...... hibition: a double-blind trial
@ast
Ulcer formation with low-dose ...... hibition: a double-blind trial
@en
Ulcer formation with low-dose ...... hibition: a double-blind trial
@nl
type
label
Ulcer formation with low-dose ...... hibition: a double-blind trial
@ast
Ulcer formation with low-dose ...... hibition: a double-blind trial
@en
Ulcer formation with low-dose ...... hibition: a double-blind trial
@nl
prefLabel
Ulcer formation with low-dose ...... hibition: a double-blind trial
@ast
Ulcer formation with low-dose ...... hibition: a double-blind trial
@en
Ulcer formation with low-dose ...... hibition: a double-blind trial
@nl
P2093
P1433
P1476
Ulcer formation with low-dose ...... hibition: a double-blind trial
@en
P2093
Eric S Maller
Loren Laine
Thomas Simon
P304
P356
10.1053/J.GASTRO.2004.05.001
P407
P577
2004-08-01T00:00:00Z